Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age  by Torres, Thiago Silva et al.
b r a z j i n f e c t d i s . 2 0 1 4;1  8(1):34–41
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
Original article
Incidence  rate  of  modifying  or discontinuing  ﬁrst  combined
antiretroviral therapy  regimen  due to toxicity  during  the
ﬁrst year of  treatment  stratiﬁed  by age
Thiago Silva Torresa, Sandra Wagner Cardosoa, Luciane S. Velasquea,b,
Valdilea G. Velosoa, Beatriz Grinsztejna,∗
a Instituto de Pesquisa Clínica Evandro Chagas, HIV/AIDS Clinical Research Center, Fundac¸ão Oswaldo Cruz (FIOCRUZ), Rio de Janeiro,
RJ, Brazil
b Departamento de Matemática, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 11 March 2013
Accepted  15 April 2013
Available  online 9 September 2013
Keywords:
HIV
Toxicity
Aging
Antiretroviral
a  b  s  t  r  a  c  t
Toxicity is the most frequently reported reason for modifying or discontinuing the ﬁrst com-
bined  antiretroviral therapy regimens, and it can cause signiﬁcant morbidity, poor quality
of  life and also can be an important barrier to adherence, ultimately resulting in treatment
failure  and viral resistance. Elderly patients with HIV/AIDS (≥50 years) may  have a differ-
ent  proﬁle in terms of treatment modiﬁcation due to higher incidence of comorbidities and
polypharmacy.  The aim of this study was to describe the incidence of modifying or discon-
tinuing  ﬁrst combined antiretroviral therapy regimen due to toxicity (TOX-MOD) during the
ﬁrst year of treatment at the IPEC – FIOCRUZ HIV/AIDS cohort, Rio de Janeiro, Brazil, strat-
iﬁed  by age. Demographic, clinical and treatment characteristics from antiretroviral-naïve
patients  who ﬁrst received combined antiretroviral therapy between Jan/1996 and Dec/2010
were  collected. Incidence rate and conﬁdence interval of each event were estimated using
quasipoisson  model. To estimate hazard ratio (HR) of TOX-MOD during the ﬁrst year of com-
bined  antiretroviral therapy Cox’s proportional hazards regression was applied. Overall, 1558
patients were included; 957 (61.4%), 420 (27.0%) and 181 (11.6%) were  aged <40, 40–49, and
≥50  years, respectively. 239 (15.3%) events that led to any modifying or discontinuing within
the  ﬁrst year of treatment were observed; 228 (95.4%) of these were TOX-MOD, corresponding
to  an incidence rate of 16.6/100 PY (95% CI: 14.6–18.9). The most frequent TOX-MOD during
ﬁrst  combined antiretroviral therapy regimen were hematologic (59; 26.3%), central ner-
vous  system (47; 20.9%), rash (42; 19.1%) and gastrointestinal (GI) (38; 16.7%). In multivariateanalysis,  incidence ratio of TOX-MOD during the ﬁrst year of combined antiretroviral ther-
apy  progressively increases with age, albeit not reaching statistical signiﬁcance. This proﬁlewas maintained after adjusting the model for sex, combined antiretroviral therapy regimen
and  year of combined antiretroviral therapy initiation. These results are important because
not  only patients are living longer and aging with HIV, but also new diagnoses are being
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made among the elderly. Prospective studies are needed to evaluate the safety proﬁle of ﬁrst
line combined antiretroviral therapy on elderly individuals, especially in resource-limited
countries,  where initial regimens are mostly NNRTI-based.
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13 Entroduction
he introduction of highly active antiretroviral therapy
HAART) during the 1990s was  crucial to reduce HIV related
orbidity and mortality rates turning HIV infection into a
hronic  condition. In Brazil, where HAART has been univer-
ally  available for more  than 15 years, prolonged survival has
een shown.1,2 Currently, with more  than 220,000 patients
eceiving combined antiretroviral therapy (cART), Brazil is in
 unique position to evaluate treatment outcomes of cART in
he context of developing countries.
Several studies from developed and developing countries
ave  investigated the rates and reasons for modiﬁcation or
iscontinuation of the ﬁrst cART regimen, and their results
ndicate  that up to 69% of patients may  modify their reg-
men  over time; 25–44% of them in the ﬁrst 12 months
f  treatment.3–19 The most frequently reported reason for
odifying the ﬁrst cART has been treatment-associated
oxicity5–8,10,12,13,17,19–24 that can cause signiﬁcant morbidity,
oor quality of life and can also be an important barrier to
dherence,16,25 ultimately resulting in treatment failure and
iral  resistance.26 We  have previously described that, in our
ohort,  toxicity was  the main reason for modifying or discon-
inuing  (MOD) the ﬁrst HAART regimen.5
Elderly patients (≥50 years old) with HIV/AIDS may  have
 different proﬁle in terms of treatment modiﬁcation due to
igher  incidence of comorbidities and polypharmacy.27 Also,
he  general characteristics of aging may  have considerable
nﬂuence on the pharmacokinetics of medications. These
hanges  can result in increased antiretroviral (ARV) concen-
rations,  which may  lead to higher risk of related toxicity28
nd increased rates of treatment modiﬁcations related to
oxicities.22
This study describes the incidence of MOD the ﬁrst cART
egimen due to toxicity during the ﬁrst year of treatment at
he  Evandro Chagas Clinical Research Institute, Oswaldo Cruz
oundation (IPEC – FIOCRUZ) HIV/AIDS cohort for patients who
tarted  cART in ﬁve different age groups (18–29, 30–39, 40–49,
0–59,  ≥60 years).
aterials  and  methods
escription  of  the  clinical  cohort  and  study  population
his study was  conducted at the IPEC/FIOCRUZ where care
as  been provided to HIV/AIDS patients since 1986. A longi-
udinal  observational clinical database has been maintained
n  patients receiving HIV care at IPEC. Cohort procedures
29–31
© 20ave been described and results published elsewhere.
rieﬂy, data are updated regularly using outpatient and inpa-
ient  clinical documentation and laboratory testing results.
rescription of ARV therapy (drug, dates of use, and dose) isdocumented  by the medical provider and support staff in the
clinical  records. Trained abstractors record the information
onto standardized forms for processing.
For this study, we  included data from 1558 antiretroviral
(ART)-naïve patients who ﬁrst received cART between Jan-
uary  1996 and December 2010, with follow-up through August
2011.  The IPEC Institutional Review Board has reviewed and
approved  the study.
Study  deﬁnitions
Age at HAART initiation was  the variable of interest across
all  analyses. Patients were  stratiﬁed as 18–29 years and 30–39
years  (“younger”), 40–49 years (“older”); 50–59 years and ≥60
years  (“elderly”). “Elderly” was  deﬁned according to CDC
deﬁnition for HIV/AIDS patients.32 Other variables used to
describe  our cohort included demographic, clinical and treat-
ment  related characteristics.
HIV  exposure categories were presented as: heterosexual
(women and men  separately); men  who have sex with men
(MSM);  injecting drug users (IDU), and others (not speciﬁed).
Race  was  grouped as white and non-white. Schooling was
stratiﬁed  in ≤4 years; 5–8 years; 9–11 years; >11 years. Start-
ing  cART while participating in an ART naive clinical trial,
baseline  CD4+T lymphocyte count (cells/L), baseline HIV viral
load  (log10 copies/mL) and AIDS-deﬁning disease were  also
accessed.
cART  was  deﬁned as two NRTIs in combination with at
least  one PI or one NNRTI. Patients were  grouped according
to  the year of cART initiation before and after year 2004, when
new,  less toxic and friendlier ARV options became available.
First  cART regimens were deﬁned as PI-based regimen (with or
without booster), NNRTI-based regimen and others. PI-based
regimen  that used ritonavir (RTV) as booster and the most
frequent  ﬁrst cART regimens were also recorded.
For this study, we have only assessed cART modiﬁca-
tions or discontinuations related to toxicity (TOX-MOD) that
occurred  during the ﬁrst year after treatment initiation. cART
discontinuation related to toxicity was deﬁned as treatment
interruption caused by any ARV-related toxicity. cART mod-
iﬁcation  due to toxicity was deﬁned as a toxicity driven
substitution of at least one ARV in the regimen. ARV dosage
adjustments were not considered as modiﬁcations.
The type and date of TOX-MOD were deﬁned as given in
the  medical chart, and were grouped as follows: hematologic
(anemia, thrombocytopenia, leukopenia, pancytopenia), cen-
tral nervous system (CNS) (neuropsychiatric manifestation,
e.g. hallucinations, vertigo, insomnia, nightmares, depres-
sion,  phobia), peripheral neuropathy (PN), rash, GI (nausea,
lsevier Editora Ltda.Este é um artigo Open Access sob a licença de CC BY-NC-NDvomiting, diarrhea), liver (liver enzymes increase, hyper-
bilirubinemia, jaundice), renal (creatinine clearance decrease,
serum  creatinine increase, proteinuria, lithiasis, acute renal
failure)  and metabolic (dyslipidemia and lipodystrophy).
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Statistical  analysis
The outcomes of interest were overall toxicity and the most
frequent  toxicities during the ﬁrst year after treatment initi-
ation  that had led to cART MOD  grouped as described above.
We  estimated the incidence rate and conﬁdence interval (95%
CI)  of each event stratiﬁed by age groups (18–29, 30–39, 40–49,
50–59,  ≥60 years) using quasipoisson model and reported it as
the number of occurrences per 100 persons-years (PY). Deaths
and  MOD  related to other reasons during the ﬁrst year of ART
were  censored at the time of their occurrence. Patients who
did  not MOD  their ﬁrst ART were censored at one year after
cART  initiation.
Cox’s proportional hazards regression was  applied to esti-
mate  the HR of overall TOX-MOD during the ﬁrst year of
cART  according to the clinical/demographic characteristics.
The model was  also adjusted for toxicity risk factors previ-
ously  identiﬁed (sex, type of regimen, and year of treatment
initiation).5 The proportional hazard assumption was tested
by  Schoenfeld residuals analysis.
We used the statistical software R, version 2.14.1
(www.r-project.org) for all statistical analyses.
Results
Demographic  data  and  treatment  characteristics
Selected demographic values and treatment characteristics
distributed according to the decade of life are summarized
in  Table 1. A total of 1558 ART naïve patients were  included
in  this analysis. At cART initiation, 957 (61.4%) were  younger
(<40  years), 420 (27.0%) were older (40–49 years), and 181
(11.6%)  were  elderly (≥50 years). The median age was  36 years
[interquartile range (IQR): 29–43].
Each age category had more  male (overall average of 67.2%),
and  the number of white individuals decreased with age
(54.1%  for 18–29 years and 30.6% for ≥60 years; p < 0.0043). HIV
exposure  categories signiﬁcantly ﬂuctuated over age groups
(p  < 0.001). Considering only men, the proportion of MSM  was:
48.4%,  39.7%, 41.2%, 19.3% and 18.3% for 18–29 years, 30–39
years,  40–49 years, 50–59 years and ≥60 years, respectively
(p < 0.0001). Elderly patients had less years of education (≤4
years)  than younger and older patients (14.5% for 18–29 years
and  51.4% for ≥60 years; p < 0.0001). There was  no statistically
signiﬁcant difference on ART clinical trial participation among
the  age groups.
At  the time of cART initiation, 430 (27.6%) patients had
already  presented at least one AIDS-deﬁning disease, and
the  frequency increased with age, except for patients ≥60
years  (p = 0.0247). Baseline CD4+T lymphocyte count signif-
icant  decreased with age (248 cells/L for 18–29 years and
150  cells/L for ≥60 years; p = 0.016), while there was  no sig-
niﬁcant  difference on baseline HIV viral load among the age
groups.
The  majority of patients started cART after 2004 (overall
average 68.2%); as well as the majority of patients started the
ﬁrst  cART with a NNTRI-based regimen (1088; 69.8%) and there
were  no statistically signiﬁcant differences among age groups
neither  for the calendar year nor for the regimen. RTV-boosted 0 1 4;1  8(1):34–41
PI-based regimen was  used, by 56.4% (243/431) of patients and
it  signiﬁcantly increased with age (17.0% for 18–29 years and
30.0%  for ≥60 years; p < 0.0001).
The  most frequent ﬁrst cART regimens stratiﬁed by
age  are depicted in Table 2. A combination of zidovudine
(ZDV) + lamivudine (3TC) + efavirenz (EFV) was  used by two-
ﬁfths  of the study population (628, 40.3%). Nevirapine (NVP)
was  used in 3.8% of cART regimens. Comparing NRTI use along
the  calendar year, TDF use increased after 2004, while the use
of  d4T, ddI, and ABC decreased. A continuous increase on ZDV
and  3TC use was observed from 1996 to 2010.
TOX-MOD  during  the  ﬁrst  year  of  ART
Patients were followed for a total of 1369 PY, from ART ini-
tiation  up to one year of treatment or up to any MOD  that
occurred within the ﬁrst year of treatment. A total of 239
(15.3%)  events that led to any MOD within the ﬁrst year of
treatment  were observed; 228 (95.4%) of these were  related
to  toxicity (TOX-MOD), corresponding to an incidence rate of
16.6  per 100 PY (95% CI: 14.6–18.9). The median time from ART
initiation  to TOX-MOD during the ﬁrst year of ART was  1.46
months  (IQR: 0.5–4.0). The overall probability of TOX-MOD in
the ﬁrst year of ART was  14.6% (228/1558). Almost half of the
patients  who presented TOX-MOD were  on ZDV + 3TC + EFV.
The most frequent toxicity events associated with MOD
during  the ﬁrst cART regimen were hematologic (59/228;
26.3%), CNS (47/228; 20.9%), rash (42/228; 19.1%), and GI
(38/228;  16.7%). The great majority of the hematologic events
were  anemia (48; 81.4%), followed by leucopenia (6; 10.3%). For
the GI events, the most common were nausea and vomiting
(25;  65.8%), gastrointestinal intolerance (7; 18.4%) and diarrhea
(4;  10.5%).
Frequency and incidence of TOX-MOD increased with
age  (Table 3). For younger patients the overall frequency of
TOX-MOD  was  12.0% and 14.4% (18–29 and 30–39 years, respec-
tively)  while for older and elderly patients increases of 2% and
3%  per decade of age were observed, respectively. The inci-
dence  rate of TOX-MOD for patients aged 18–29 years was  13.4
per  100 PY (95% CI: 10.1–17.6) while for patients aged 50–59
years,  and ≥60 years was  19.4 per 100 PY (95% CI: 13.0–29.0) and
22.8  per 100 PY (95% CI: 10.9–47.8), respectively. Stratifying by
age  groups, both frequency and incidence increased with age
for  most of toxicities, and this increase was  more  pronounced
from  40 to 49 years and above. In contrast, the incidence rate of
TOX-MOD  by gastrointestinal events was much  higher among
patients  aged 30–39 years (44.0 per 100 PY (95% CI: 28.4–68.2).
Frequency of liver, renal, PN and metabolic toxicities was  low
in  this study.
The  results of the multivariate model (Cox’s proportional
hazards regression) showed that the incidence ratio of TOX-
MOD  during the ﬁrst year of cART progressively increased with
age,  albeit not reaching statistical signiﬁcance. This proﬁle was
maintained  after adjusting for sex, cART regimen and year of
cART  initiation: HR 1.18 (95% CI: 0.82–1.68) for 30–39 years;
HR  1.41 (95% CI: 0.97–2.03) for 40–49 years; HR 1.42 (95% CI:
0.87–2.30)  for 50–59 years; HR 1.61 (95% CI: 0.73–3.55) for ≥60
years  (Table 4). No violation of Schoenfeld proportional hazard
assumption  was found.
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Table 1 – Demographics, clinical, and HIV treatment characteristics of individuals at IPEC – FIOCRUZ HIV/AIDS cohort
stratiﬁed by age at cART initiation.
Variable Younger Older Elderly Total p-Value
18–29 30–39 40–49 50–59 ≥60
Patients, nr. (%) 417  (26.7) 540  (34.6) 420  (26.9) 145 (9.3) 36 (2.3) 1558 0.008
Men (%) 285 (68.3) 358 (66.3) 294 (70.0) 88 (60.7) 22 (61.1) 1047 (67.2) 0.254
HIV exposure categories, nr. (%)
Heterosexual  (women) 117 (30.5) 161 (33.1) 104 (28.0) 47 (37.9) 10 (33.3) 439 (28.2) <0.001
Heterosexual (men) 72 (18.8) 108 (22.2) 89 (23.9) 45 (36.3) 13 (43.3) 327 (31.2)
MSM 138 (35.9) 142 (29.2) 121 (32.5) 17 (13.7) 4 (13.3) 422 (40.3)
IDU 2 (0.5) 3 (0.6) 3 (0.8) 0 0 8 (0.6)
Others 55 (14.3) 72 (14.8) 55 (14.8) 15 (12.1) 3 (10.0) 200 (14.3)
Race, nr. (%): white 225 (54.1) 318 (59.1) 243 (58.0) 72 (49.7) 11 (30.6) 869 (55.8) 0.004
Schooling, nr. (%)
≤4  60 (14.5) 119 (22.2) 81 (19.4) 46 (31.7) 18 (51.4) 324 (20.8) <0.001
5–8 102 (24.6) 164 (30.6) 128 (30.7) 36 (24.8) 4 (11.4) 434 (27.8)
9–11 184 (44.3) 173 (32.3) 126 (30.2) 38 (26.2) 8 (22.9) 529 (33.9)
>11 69 (16.6) 80 (14.9) 82 (19.7) 25 (17.2) 5 (14.3) 261 (16.7)
Baseline CD4+ T lymphocyte
count  (cells/L) median (IQR)
248  (137–339) 216  (96–313) 203  (94–320) 206  (116–294) 150 (86–254) 222 (105–322) 0.016
Baseline HIV viral load
(log10 copies/mL) median (IQR)
4.8 (4.2–5.4) 5.0 (4.4–5.5) 5.0 (4.3–5.5) 4.9 (4.4–5.4) 5.1 (4.5–5.7) 5.0 (4.3–5.5) 0.144
AIDS-deﬁning disease 94 (23.0) 148 (27.7) 132 (32.3) 48 (33.3) 8 (23.5) 430 (27.6) 0.025
ART clinical trial participation 146 (35.1) 179 (33.1) 123 (29.5) 41 (28.5) 6 (17.1) 495 (31.8) 0.102
Year of cART initiation
>2004  287 (68.8) 349 (64.6) 293 (69.8) 108 (74.5) 25 (69.4) 1062 (68.2) 0.172
≤2004 130 (31.2) 191 (35.4) 127 (30.2) 37 (25.5) 11 (30.6) 496 (31.8)
First cART
NNRTI 289 (69.8) 381 (71.3) 292 (70.5) 105 (72.4) 21 (58.3) 1088 (69.8) 0.751
PI (with or without booster) 121 (29.2) 145 (27.2) 114 (27.5) 37 (25.5) 14 (38.9) 431 (27.7)
Others 4 (1.0) 8 (1.5) 8 (1.9) 3 (2.1) 1 (2.8) 24 (1.5)
PI with booster (RTV) 71 (17.0) 71 (13.1) 72 (17.1) 30 (16.7) 9 (30.0) 243 (15.6) <0.001
IQR, interquartile range.
Table 2 – Most frequent ﬁrst cART regimens at IPEC – FIOCRUZ HIV/AIDS cohort stratiﬁed by age at cART initiation.
First cART regimens Younger Older Elderly Total
18–29
n  = 417 (26.7%)
30–39
n  = 540 (34.6%)
40–49
n  = 420 (26.9%)
50–59
n = 145 (9.3%)
≥60
n  = 36 (2.3%)
n = 1558
ZDV + 3TC + EFV 151 (36.1) 218 (40.4) 173 (41.2) 74 (51.0) 12 (33.3) 628 (40.3%)
TDF + 3TC + EFV 50 (12.0) 50 (9.3) 49 (11.7) 10 (6.9) 4 (11.1) 163 (10.5%)
FTC + TDF + EFV 40 (9.6) 50 (9.3) 33 (7.9) 12 (8.3) 0 135 (8.7%)
ZDV + 3TC + LOP/r 15 (3.6) 19 (3.5) 23 (5.5) 5 (3.4) 3 (8.3) 65 (4.2%)
TDF + 3TC + ATV/r 15 (3.6) 14 (2.6) 13 (3.1) 1 (0.7) 1 (2.8) 44 (2.8%)
ZDV + 3TC + NFV 6 (1.4) 21 (3.9) 13 (3.1) 1 (0.7) 0 41 (2.6%)
d4T + 3TC + EFV 9 (2.1) 18 (3.3) 8 (1.9) 3 (2.1) 3 (8.3) 41 (2.6%)
FTC + ddI + ATV 10 (2.4) 10 (1.8) 10 (2.4) 4 (2.8) 1 (2.8) 35 (2.3%)
nosi
D
O
l
a
a
R3TC, lamivudine; ATV/r, atazanavir/ritonavir; d4T, stavudine; ddI, dida
nelﬁnavir; TDF, tenofovir; ZDV, zidovudine.
iscussion
ur results provide important insights into the toxicities that
ed  to ﬁrst line cART MOD  during the ﬁrst year of treatment as
 function of age at cART initiation among patients followed
t  a clinical research institute in a middle-income country.
oughly 95% of the ﬁrst ART regimen MOD  was  related tone; EFV, efavirenz; FTC, emtricitabine; LOP/r, lopinavir/ritonavir; NFV,
toxicity.  Hematologic, CNS, rash and GI were  the most fre-
quently  reported causes of TOX-MOD. These results are
important because not only patients are living longer and
aging  with HIV, but also new diagnoses are being made among
33–35the  elderly. In a previous assessment on the incidence
of  MOD of the ﬁrst cART regimen in our cohort, evaluating
670  patients who started cART between 1996 and 2006, tox-
icities  within the ﬁrst year of treatment were  observed in
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Table 3 – Incidence rate of TOX-MOD on the ﬁrst cART regimen at IPEC – FIOCRUZ HIV/AIDS cohort stratiﬁed by age at cART initiation.
MOD Younger Older Elderly Total n = 1558
18–29 years
n  = 417 (26.7%)
30–39 years
n = 540 (34.6%)
40–49 years
n = 420 (26.9%)
50–59 years
n  = 145 (9.3%)
≥60 years
n  = 36 (2.3%)
n (%) Rate/100 PY
n (%) Rate/100 PY n (%) Rate/100 PY n (%) Rate/100 PY n (%) Rate/100 PY n (%) Rate/100 PY
Overall
toxicity
50  (12.0) 13.4 (10.1–17.6) 78 (14.4) 16.4 (13.2–20.5) 69 (16.4) 18.8 (14.9–23.9) 24 (19.2) 19.4 (13.0–29.0) 7 (23.3) 22.8 (10.9–47.8) 228 (14.6) 16.6 (14.6–18.9)
Hematologic 11 (2.6) 31.1 (17.2–56.2) 20 (3.7) 44.0 (28.4–68.2) 20 (4.8) 58.2 (37.5–90.1) 6 (4.1) 50.6 (22.7–112.5) 2 (5.6) 66.6 (16.7–266.4) 59 (3.8) 4.3 (3.3–5.6)
CNS 15 (3.6) 42.5 (25.6–70.4) 10 (1.8) 22.0 (11.8–40.9) 16 (3.8) 46.5 (28.5–75.9) 4 (2.7) 33.7 (12.6–89.8) 2 (5.6) 66.6 (16.7–266.4) 47 (3.0) 3.4 (2.6–4.6)
Rash 8 (1.9) 22.6 (11.3–45.3) 12 (2.2) 26.4 (15.0–46.5) 13 (3.1) 37.8 (22.0–65.1) 9 (6.2) 75.8 (39.4–145.7) 0 0 42 (2.7) 3.1 (2.3–4.2)
Gastrointestinal 7 (1.7) 19.8 (9.4–41.6) 20 (3.7) 44.0 (28.4–68.2) 7 (1.7) 20.4 (9.7–42.7) 2 (1.4) 16.8 (4.2–67.4) 2 (5.6) 16.8 (4.2–67.4) 38 (2.4) 2.8 (2.0–3.8)
Liver 5 (1.2) 14.1 (5.9–34.0) 5 (0.9) 11.0 (4.6–26.4) 2 (0.5) 5.8 (1.4–23.2) 2 (1.4) 16.8 (4.2–67.4) 0 0 14 (0.9) 1.0 (0.6–1.7)
Renal 1 (0.2) 2.8 (0.4–20.1) 5 (0.9) 11.0 (4.6–26.4) 2 (0.5) 5.8 (1.4–23.2) 0 0 1 (2.8) 33.3 (4.7–236.5) 9 (0.6) 0.7 (0.3–1.3)
Metabolic 1 (0.2) 2.8 (0.4–20.1) 0 0 1 (0.2) 2.9 (0.4–20.6) 0 0 0 0 2 (0.1) 0.1 (0.04–0.58)
Peripheral
neuropathy
1 (0.2) 2.8 (0.4–20.1) 2 (0.4) 4.4 (1.1–17.6) 0 0 1 (0.7) 8.4 (1.2–59.8) 0 0 4 (0.2) 0.3 (0.1–0.8)
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Table 4 – Hazard ratio (HR) and 95% conﬁdence interval (95% CI) estimated by Cox proportional hazards regression of
TOX-MOD on ﬁrst cART at IPEC – FIOCRUZ HIV/AIDS cohort stratiﬁed by age at cART start.
Age category Unadjustuded  Adjusting for sex, ﬁrst cART
regimen  and year of ART initiation
HR (95% CI) p-Value HR (95% CI) p-Value
18–29 years 1 – 1 –
30–39 years 1.22 (0.86–1.75) 0.26 1.18 (0.82–1.68) 0.36
40–49 years 1.39 (0.96–2.00) 0.07 1.41 (0.97–2.03) 0.06
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b50–59 years 1.43 (0.88–2.33) 0
≥60 years 1.66 (0.75–3.67) 0
6.7%, corresponding to an incidence rate of 24 per 100 PY
95%  CI: 20.0–28.0),5 much  higher than the observed in this
tudy  (14.6%). This difference can be attributed to the larger
umber  of patients in our cohort who started therapy after
006,  when the use of friendlier, less toxic NRTIs and PIs have
ramatically  increased, when compared to the initial HAART
eriod  until 2006. The same proﬁle of TOX-MOD during the
rst  year of treatment was  found in the Caribbean, Central
nd  South America Network for HIV Research (CCASAnet)
ohort, with adverse events prompting ART regimen change in
4.4% of patients initiating a HAART regimen, among six of the
even  participating clinical sites. Similar to what was  found in
ur cohort, in this multicenter Latin America cohort, hemato-
ogic  events, 70% of which anemia, were  the most frequently
bserved toxicity.6
Until very recently in 2012, the Brazilian ARV guide-
ines preferential option for ﬁrst cART regimen consisted
f  ZDV + 3TC + EFV.36 This may  explain the toxicity proﬁle
bserved, with hematologic and GI events as the most com-
only  reported, probably associated with ZDV, and CNS and
ash  events, commonly related to EFV.
The high use of LPV/r and ATV/r as second options for
rst-line regimen can also explain the high frequency of GI
oxicities.  However, these observations are based on previous
tudies,  and this study focused on the overall incidence of tox-
cities stratiﬁed by age rather than class-related (NRTI, NNRTI,
I)  or even ARV-related toxicities. The use of PI with booster
ncreased with age (Table 1) and no association with calen-
ar  year was  identiﬁed. We noticed that at the time of cART
nitiation,  almost 30% of our patient population had already
resented at least one AIDS-deﬁning disease, and this fre-
uency  increased with age. Furthermore, CD4+T lymphocyte
epletion signiﬁcantly increased with age. It is well known
hat  clinicians tended to prescribe more  PI based regimens
ith  booster for individuals with more  advanced immuno-
uppression, and this may  have had an impact on the ARV
rescription pattern in our cohort. It could also be the case that
atients  and their providers could have feared EFV related CNS
oxicity among older individuals, and thus PI-based regimens
ith  booster were  more  prescribed among these patients.
A  high incidence of CNS related toxicities on individuals
ged 18–29 years (42.5 per 100 PY; 95% CI: 25.6–70.4) when com-
ared  to those aged 30–39 years (22.0/100 PY; 95% CI: 11.8–40.9)
as  observed. Data on the use of recreational drugs were not
vailable  for our cohort. We can speculate that a higher use of
uch  drugs among young HIV-infected individuals in our study
opulation  could be contributing to this ﬁnding. Interactions
etween agents commonly prescribed for patients with HIV1.42 (0.87–2.30) 0.16
1.61 (0.73–3.55) 0.23
and  recreational drugs can occur. Clinicians should encour-
age  open dialog with their patients on this topic, to avoid the
risk  of drug toxicity.37 Further studies on this topic should be
encouraged.
Metabolic,  liver, renal and PN related toxicities are more
common on the long term, and this could explain the low fre-
quency  observed up to one year of cART, which precluded us
to  compare the frequency and incidence differences of these
events  among the age groups.
In the multivariate model adjusted for sex, ﬁrst cART regi-
men  and calendar year of cART initiation, the HR for TOX-MOD
increased with age, although this effect did not reach sta-
tistical  signiﬁcance. The limited number of patients on the
elderly  group, especially ≥60 years, could have inﬂuenced
these results.
Increased risk of toxicity related to cART among elderly
individuals was  previously observed.38–40 However, very
limited data comparing TOX-MOD of ﬁrst cART among differ-
ent  age groups have been reported, and the few comparisons
available41–43 were  done between two major age groups only
(<50  years and ≥50 years, elderly). Moreover, previous anal-
ysis  neither for Latin America nor for developing countries
from  other regions was found. In a study from the Italian
Cohort Naïve Antiretrovirals (ICoNA) a signiﬁcantly higher risk
of  TOX-MOD on elderly was  observed, and this difference in
the  signiﬁcance may  be attributed to the higher number of
elderly  in comparison with our population (<50 years, n = 4818;
≥50  years, n = 399).41 In a cohort from France, TOX-MOD
of ﬁrst cART regimens was  independently associated with
age  and occurs at earlier stages of treatment in individuals
≥50  years. Consistent with our ﬁndings, a higher frequency
of  CNS and hematologic events on elderly people was
observed.42
Other authors have also studied the impact of age on TOX-
MOD  but due to the different methodology and deﬁnitions
applied, comparisons are difﬁcult. In a study from the UK,
MOD  for reasons other than virological failure during the ﬁrst
year  of cART was  higher in those aged <30 years and ≥50
years.  Although TOX-MOD was  not studied separately, a higher
frequency  of laboratory abnormalities among the elderly pop-
ulation,  specially a decrease in hemoglobin count, could be
associated  with this ﬁnding.43
Recently published results from the PEARLS study
have shown that a regimen consisting of tenofovir
(TDF) + emtricitabine (FTC) + EFV has shown a better safety
proﬁle  than ZDV + 3TC + EFV, with less hematologic and CNS
related  toxicities, and can be potentially a better regimen for
the  elderly individuals.44
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Elderly individuals are prone to develop other clinical con-
ditions  typical of an aging population, and the medications
used to treat such comorbidities may  interact with ARV drugs
leading  to a higher incidence of toxicity. As elderly individuals
have  been shown to be more  adherent to therapy related45 tox-
icities  may  also be more  frequently given higher cumulative
exposure to the drugs.
Our  study has limitations. The retrospective nature of the
data  collection process implies that biases may  have inﬂu-
enced  our results. Also, we have not assessed toxicities related
to  cART that did not result in MOD,  toxicity grading and
patient’s adherence level.
Prospective  studies are needed to evaluate the safety proﬁle
of  ﬁrst line cART on elderly individuals, especially in resource-
limited  countries, where initial regimens are mostly NNRTI
based.
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